Search for any words: Search

                            

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Attal, Michel ,  Palumbo, Antonio ,  Holstein, Sarah ... -  ASCO -  J. Clin. Oncol. -  2016  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma      

Holstein, Sarah A. ,  Jung, Sin-Ho ,  Richardson, Paul G. ... -  -  Lancet Haematol -  2017  

Manuscript -  Primary Endpoint -  Long-Term-Followup Analysis -  Myeloma -  CALGB-100104

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. ,  Owzar, Kouros ,  Richardson, Paul G. ... -  ASCO -  J. Clin. Oncol. -  2015  

Abstract -  Primary Endpoint -  Long-Term-Followup Analysis -  Myeloma -  CALGB-100104

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. ,  Holstein, Sarah A. ,  Jung, Sin-Ho ... -  ASCO -  J. Clin. Oncol. -  2017  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

McCarthy, Philip L. ,  Holstein, Sarah A. ,  Jung, Sin-Ho ... -  IMW -  -  2017  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. ,  Holstein, Sarah A. ,  Jung, Sin-Ho ... -  EHA -  Haematologica -  2017  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis      

McCarthy, Philip L. ,  Holstein, Sarah A. ,  Petrucci, Maria Teresa ... -  -  J. Clin. Oncol -  2017  

Manuscript -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma      

McCarthy, Philip L. ,  Owzar, Kouros ,  Hofmeister, Craig C. ... -  -  N. Engl. J. Med. -  2012  

Manuscript -  Primary Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)   

McCarthy, Philip L. ,  Suman, Vera ,  Cooper, Miranda ,  Saunders, Owain ... -  ASH -  Blood -  2018  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104   

Mccarthy, P. ,  Owzar, K. ,  Hofmeister, C. ,  Richardson, P. ... -  IMW -  Clin Lymphoma Myeloma Leuk -  2013  

Abstract -  Secondary-not-in-original Endpoint -  Primary Analysis -  Myeloma -  CALGB-100104

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29

Voorhees, Peter M. ,  Kaufman, Jonathan L. ,  Laubach, Jacob ... -  IMW -  -  2019  

Abstract -  Primary Endpoint -  Primary Analysis -  Myeloma -  AFT-29

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Voorhees, Peter M. ,  MD ,  Costa, Luciano J. ,  PhD ,  Reeves, Brandi ... -  ASH -  Blood -  2017  

Abstract -  Secondary Endpoint -  Preliminary Analysis -  Myeloma -  AFT-29

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Voorhees, Peter M. ,  Mulkey, Flora ,  Hassoun, Hani ... -  ASH -  Blood -  2015  

Abstract -  Primary Endpoint -  Primary Analysis -  Myeloma -  A061202

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Voorhees, Peter M. ,  Rodriguez, Cesar ,  Reeves, Brandi ... -  ASH -  Blood -  2018  

Abstract -  Primary Endpoint -  Primary Analysis -  Myeloma -  AFT-29